« Return to News | Awards & Advancement

Inovio's chairman elected fellow by AAAS

Wednesday, March 14, 2012 09:16 AM

Inovio Pharmaceuticals’ advisory board chairman David B. Weiner, PhD, has been elected a fellow in the nonprofit American Association for the Advancement of Science (AAAS).

Weiner, sometimes called the "father of synthetic DNA vaccines," was honored for his pioneering and enabling discoveries in the area of synthetic DNA vaccines and promoting the nascent field of research during its early stages. He was recognized at the Fellows Forum held February 18 in Vancouver, Canada.

A professor in the department of pathology and laboratory medicine at the University of Pennsylvania, Weiner helped to found the field of synthetic DNA vaccines in the early 1990s. His laboratory and collaborators were responsible for the first synthetic DNA vaccine Investigational New Drug application (IND). This IND for HIV immune therapy became the first IND approved as a synthetic DNA therapeutic vaccine. His studies were the first to establish that synthetic DNA vaccines appear well tolerated and are immunogenic in humans.

The AAAS Fellowship is based on scientifically or socially distinguished efforts to advance science or its applications. Members have been elected to the organization by their peers since 1874.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.